CDER’s Critical Path Innovation Meeting Program

CDER’s Critical Path Innovation Meeting Program

The Critical Path Innovation Meeting (CPIM) Program provides an opportunity for outside stakeholders to communicate directly with FDA subject matter experts to discuss potential scientific advancements in drug development. Within the CPIM setting, representatives from FDA and industry, academia, patient groups, scientific consortia and other organizations can have an open scientific discussion and exchange of ideas with a common goal of improving efficiency and success in drug development. CPIM discussions are non-binding on FDA and the requestor, and do not provide advice on a specific approval pathway, FDA policy, or guidance.

For more information, about this program please contact the CPIM Inquiries Mailbox or visit our website.